Anifrolumab Breastfeeding Study
Have you taken SAPHNELO™ (anifrolumab) for the treatment of your Systemic Lupus Erythematosus (SLE)? Are you currently 18 or older and either exclusively breastfeeding or pregnant and planning to exclusively breastfeed your infant?
Lupus can be a debilitating condition. Help future breastfeeding women, doctors and researchers understand the safety of SAPHNELO™ (anifrolumab) when used by breastfeeding individuals with lupus.
I am a patientAre you a healthcare provider who treats pregnant or breastfeeding women with systemic lupus erythematosus?
Help us learn more about the safety of SAPHNELO™ (anifrolumab) when used by lupus erythematosus patients during breastfeeding.
I am a Healthcare Provider
About the SAPHNELO™ (anifrolumab) Breastfeeding Study
The goal of the SAPHNELO™ (anifrolumab) Breastfeeding Study is to help patients, doctors, and researchers better understand the safety of SAPHNELO™ (anifrolumab) when used by breastfeeding individuals with lupus.
Breastfeeding individuals with lupus living in the United Sates who are using SAPHNELO™ (anifrolumab) may be eligible to participate in this study.
The study collects health information, milk samples, and blood samples. Eligible participants will provide information and samples for 30 days. Samples will be collected postpartum: at least 85 days after delivery or after 3 consecutive doses of anifrolumab. The study also collects information and a small blood sample from infants. The information is analyzed to learn whether a medicine can be transferred to the infant through breast milk.
Would you like to participate?
Learn more about the study
Alternatively call the study team voicemail toll-free at 877-311-3793 and leave your name and number (you can call at any time of the day to leave a message, your call will be returned during the operation hours 8:30 am – 5:00 pm EST Monday-Friday)